drugset / Trial / NCT04034225
Addition of SNS-301 to Checkpoint Inhibitor Treatment in Metastatic/Recurrent SCCHN
NaSingle-groupOpen-labelTreatment
Summary
To evaluate safety, immunogenicity and anti-tumor responses of intradermally delivered SNS-301 added to checkpoint inhibitor therapy in locally advanced unresectable or metastatic/recurrent squamous cell carcinoma of the head and neck (SCCHN) patients.
Timeline
- Start
- 2019-11-11
- Primary completion
- 2021-06-28
- Completion
- 2021-06-28
Outcome
Outcome not reported
Stopped: “Terminated by the sponsor”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Pembrolizumab | Monoclonal antibody | 200 mg | Intravenous |
| Subject | Pembrolizumab | Monoclonal antibody | 400 mg | Intravenous |
| Subject | SNS-301 | Unknown | — | Other |